Key result
The ACE II genotype was associated with an increased risk of diabetes in cardiovascular disease patients, though significance was lost after adjustment.
Why the study?
The association of the angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism with the risk of diabetes in patients with cardiovascular disease was not known.
Does the ACE I/D polymorphism increase the risk of diabetes in patients with cardiovascular disease?
Observational (n=531)
Does the ACE I/D polymorphism increase the risk of diabetes in patients with cardiovascular disease?
Answers are grounded in this paper and cite their sources.
The ACE II genotype may be associated with an increased risk of diabetes in patients with cardiovascular disease, though this effect appears confounded by age and gender.
Angiotensin converting enzyme (ACE), as part of renin angiotensin aldosterone system, is involved in blood pressure regulation and control several physiological functions. Insertion/Deletion (I/D) polymorphism of ACE has pronounced effects on development of metabolic diseases like diabetes, cardiovascular diseases (CVDs) and hypertension. However, association of I/D polymorphism with risk of diabetes in CVD patients is not known. The aim of present study was to check the association of ACE I/D polymorphism with risk of diabetes in subjects with CVD. For this, 531 subjects were sampled and divided into 3 groups; G1-H (healthy controls, n=117), G2-CN (cardiac patients without diabetes, n=271) and G3-CD (cardiac patients with diabetes, n=143). Genotyping of ACE I/D polymorphism was done by polymerase chain reaction. Allelic and genotypic frequencies were in Hardy Weinberg Equilibrium (χ2=0.11, p>0.05) and revealed high prevalence of I allele (55%) among all groups. However, II genotype was more common (37%) in G3-CD group. Level of glucose was also higher in subjects with II genotype than DD genotype (12.6±6.3 mmol/L vs. 9.7±5.1 mmol/L). Logistic regression analysis revealed that ACE II genotype increase the risk of diabetes in CVD patients by ~2 times [OR=1.94, CI: 1.24–3.01, p=0.03]; however, this association did not reach the significance level when adjusted for age and gender. In conclusion, ACE I/D polymorphism influence the risk of diabetes in CVD patients and ACE II increases this risk by ~2 fold.
No takes yet. Share an insight, caveat, or question.
Hussain et al. (2019) conducted an observational in Cardiovascular disease and diabetes (n=531). ACE II genotype vs. Other ACE genotypes was evaluated on Risk of diabetes (OR 1.94, 95% CI 1.24-3.01, p=0.03). The ACE II genotype was associated with an increased risk of diabetes in cardiovascular disease patients, though significance was lost after adjustment.
Synapse has enriched 10 related papers. Consider them for comparative context: